Testing bisoprolol and verapamil in hypertrophic heart disease
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have non-obstructive hypertrophic cardiomyopathy with thickened heart muscle (wall thickness at least 15 mm) not caused by other diseases like uncontrolled high blood pressure, valve problems, or storage diseases
- You have symptoms or heart strain, such as at least NYHA class II, a past history of NYHA class II, high BNP/Pro-BNP blood test levels, or non-sustained fast rhythm on a recent heart recording
- Your heart pumping strength (ejection fraction) is 50% or higher
- Your heart’s outflow blockage is not too high (LVOT gradient 30 mmHg or less at rest or during certain maneuvers)
- You can understand study information and do required tests (including an exercise test) and can communicate in Danish
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new study drug (BHB-1893) with a standard heart medication called metoprolol to see which one better improves symptoms in people with obstructive hypertrophic cardiomyopathy. If you join, you will be randomly assigned to receive either the study drug or metoprolol, and your symptoms and heart function will be monitored over time.
This trial tests a new medication called baxdrostat that may help reduce thickening of the heart's main pumping chamber (left ventricular hypertrophy), which is often caused by high blood pressure. The study will see if this drug helps improve heart health in people with this condition.
This trial tests whether a genetic test can help doctors choose the best beta blocker for people with heart failure who have mildly reduced pumping function. It aims to improve treatment by matching the drug to your genetic profile.
This study looks at how mineralocorticoid-related hormone signaling affects small heart blood vessels and how efficiently the heart works in people with high blood pressure. It may help doctors understand which treatments could improve heart function in hypertension.
This trial tests a new medicine, HJB647, in people with heart failure who have a weak heart pump. It aims to see if the drug is safe and well-tolerated. You may qualify if your heart's pumping ability is reduced and you are on a specific standard therapy.
This study tests a device called a coronary sinus reducer for people with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened) who still have symptoms like chest pain. The device is placed in a vein of the heart to improve blood flow and reduce symptoms.
Hear when a new Non-obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.